gsk & novartis, page-5

Hi Coolviews & coppertop01,

As we are beginning to see the playing field of pharmaceuticals is changing and evolving in ways that even 10 years ago we would never have imagined. Alliances are now being forged with the intent to become “market leaders” not “market followers” and GSK is one of those “leaders”. In the words of John Baldoni, GlaxoSmithKline’s SVP of Platform Technology and Science,

“…….urged the audience to start looking at the world of medicine differently. Unprecedented “coopetition” among Big Pharma’s and the current shift in thinking around what constitutes competitive versus pre-competitive intelligence have significant implications for drug delivery”

Begin to ring true. Creating the world’s largest OTC business now opens up more possibilities as you have identified coppertop01, for the utilising of OBJ’s technologies. The unfortunate problem is that there are lengthy lead times in bringing a product to market, which I for one didn’t fully realise, but what we hope will happen on Monday may give us an indication of a time line and more importantly a better understanding of the process involved.